Back to PFE Stock Lookup

PFE – Press Releases

Apr 14, 2014 07:02 AM Advil® Relief in Action and Josh Duhamel Celebrate National Volunteer Week with Points of Light & Kick off a Nationwide “Relief” Tour
Apr 6, 2014 10:30 AM Pfizer’s Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole Significantly Prolonged Progression-Free Survival in Patients with Advanced Breast Cancer
Apr 1, 2014 02:30 PM ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool
Mar 28, 2014 06:26 PM Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium® 24HR
Mar 27, 2014 08:14 AM In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Contro
Mar 27, 2014 08:00 AM Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study1
Mar 26, 2014 08:00 AM Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age
Mar 25, 2014 05:10 PM Pfizer Invites Public To View And Listen To Webcast Of May 5 Conference Call With Analysts
Mar 25, 2014 08:30 AM Pfizer Reports Positive Phase 3 Study Outcome Of XALKORI® (crizotinib) Compared To Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Mar 22, 2014 11:45 AM Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis
Mar 20, 2014 08:30 AM Pfizer’s Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease
Mar 19, 2014 09:45 AM ViiV Healthcare Announces Next Round of the Positive Action Southern Initiative to Support Linkages to HIV/AIDS Care and Treatment Adherence
Mar 18, 2014 10:00 AM Pfizer Launches 2013 Integrated Annual Review
Mar 14, 2014 01:00 PM U.S. FDA Approves Eliquis® (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery
Mar 12, 2014 02:28 PM Pfizer Will Appeal Court Decision Regarding Celebrex Reissue Patent
Mar 12, 2014 10:00 AM Pfizer Announces Webcast Of April 6 Conference Call With Securities Analysts To Review Palbociclib Phase 2 Final Results Following Presentation At AACR Annual Meeting 2014
Mar 12, 2014 06:37 AM Pfizer Presents Detailed Results From Landmark Community-Acquired Pneumonia Immunization Trial In Adults (CAPiTA) Evaluating Efficacy Of Prevenar 13*
Mar 6, 2014 05:15 PM Pfizer Initiates Nationwide Voluntary Recall of Two Lots of Pfizer’s Effexor XR® 150 Mg Extended-Release Capsules and One Lot of Greenstone’s Venlafaxine HCl 150 Mg Extended-Release Capsules Due
Mar 5, 2014 01:13 PM Price Movements, Clinical Trial Results, and Solid Financial Reports - Analyst Notes on Pfizer, Dendreon, DepoMed, Globus Medical, and Array
Feb 26, 2014 08:00 AM Nodality, Inc. Appoints Ralph Snyderman, M.D., to Board of Directors
Feb 24, 2014 11:45 AM Pfizer Announces FDA Approval to Include Radiographic Data on Reduction of Progression of Structural Joint Damage for Adults with Moderately to Severely Active Rheumatoid Arthritis in Labeling for XEL
Feb 24, 2014 07:00 AM Pfizer Announces Positive Top-Line Results Of Landmark Community-Acquired Pneumonia Immunization Trial In Adults (CAPiTA) Evaluating Efficacy Of Prevenar 13*
Feb 21, 2014 11:06 AM In a Subanalysis, Eliquis® (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular
Feb 18, 2014 10:00 AM Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
Feb 13, 2014 07:00 AM Seven Leading Health Organizations Join Optum Labs Research Collaborative
Feb 11, 2014 02:03 PM Pfizer Statement on Today’s Joint Meeting of FDA Advisory Committees
Feb 5, 2014 06:45 AM Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies
Feb 4, 2014 08:00 AM Pain Therapeutics Reports 2013 Financial Results and Provides Guidance for 2014
Feb 3, 2014 07:00 AM Pfizer Announces Positive Top-Line Results From PALOMA-1 Evaluating Palbociclib Plus Letrozole in Women with Advanced Breast Cancer
Jan 28, 2014 07:00 AM Pfizer Reports Fourth-Quarter and Full-Year 2013 Results; Provides 2014 Financial Guidance
Jan 27, 2014 07:00 AM Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer
Jan 23, 2014 08:00 AM Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study
Jan 22, 2014 10:00 AM New Survey Reveals What Match.Com Members Think About Smoking Cigarettes And Dating
Jan 22, 2014 07:30 AM Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP
Jan 21, 2014 08:00 AM CHANTIX®/CHAMPIX® (varenicline) Demonstrates Smoking-Cessation Efficacy In Smokers Unwilling or Unable To Quit Abruptly
Jan 21, 2014 06:52 AM ViiV Healthcare's new HIV medicine Tivicay™ (dolutegravir) is approved in Europe
Jan 17, 2014 10:15 AM Statement from Pfizer Chief Medical Officer on the 50th Anniversary of the First Surgeon General's Report on Smoking and Health
Jan 13, 2014 08:00 AM Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With

Back to PFE Stock Lookup